378758-70-4 Usage
General Description
(4-Chloro-5-methyl-3-trifluoromethyl-pyrazol-1-yl)-acetic acid, also known as CMTPA, is a chemical compound that belongs to the pyrazole class. It is a derivative of acetic acid and contains a pyrazole ring with a chlorine atom at the 4th position, a methyl group at the 5th position, and a trifluoromethyl group at the 3rd position. CMTPA has various potential applications, including as a building block in organic synthesis, as a pharmaceutical intermediate, and as a research chemical for studying the properties and reactivity of pyrazole derivatives. Its unique structure and functional groups make it a valuable compound for use in chemical and pharmaceutical industries.
Check Digit Verification of cas no
The CAS Registry Mumber 378758-70-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 3,7,8,7,5 and 8 respectively; the second part has 2 digits, 7 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 378758-70:
(8*3)+(7*7)+(6*8)+(5*7)+(4*5)+(3*8)+(2*7)+(1*0)=214
214 % 10 = 4
So 378758-70-4 is a valid CAS Registry Number.
InChI:InChI=1/C7H6ClF3N2O2/c1-3-5(8)6(7(9,10)11)12-13(3)2-4(14)15/h2H2,1H3,(H,14,15)
378758-70-4Relevant articles and documents
ANTAGONISTS OF CHEMOKINE RECEPTORS
-
, (2014/03/24)
Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are generally aryl piperazine derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated diseases, and as controls in assays for the identification of competitive CCR1 antagonists.
1-ARYL-4-SUBSTITUTED PIPERAZINES DERIVATIVES FOR USE AS CCR1 ANTAGONISTS FOR THE TREATMENT OF INFLAMMATION AND IMMUNE DISORDERS
-
Page 76, (2008/06/13)
Compounds are provided that act as potent antagonists of the CCR1 receptor, and which have been further confirmed in animal testing for inflammation, one of the hallmark disease states for CCR1. The compounds are generally aryl piperazine derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated diseases, and as controls in assays for the identification of competitive CCR1 antagonists.
